We have limited Spanish content available. View Spanish content.

In Vivo

Show me the money

Show me the money

Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.

By Anil Shrivastava, David Bellaire and Ashish Singh

  • min read

Article

Show me the money
en

Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.

Download the Full Report (pdf)
Tags

How We've Helped Clients

A Medical Imaging Company’s CX Overhaul Boosts Customer Satisfaction and Revenue

See more related case studies

A healthcare payer sets its own long-term health strategy

See more related case studies

A Regional Operating Model Lifts European Sales for a Medical Device Maker

See more related case studies

Want to continue the conversation

We help global leaders with their organization's most critical issues and opportunities. Together, we create enduring change and results

Contact Bain

How can we help you?

See all offices